# Rocket Pharmaceuticals, Inc. (RCKT) · Edgar & Edgarette company card

> Rocket Pharmaceuticals (RCKT) reported revenue of $0 million in FY2025, operating margin null against a -3.8% median for pharmaceutical preparations, equity 83.9% of assets. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 1281895 · fiscal year ended 2025-12-31 · 5 audited years read · [page](https://www.pops4.com/boards/company/RCKT) · [JSON](https://www.pops4.com/boards/company/RCKT.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $0 |
| Revenue growth, 1 year | — |
| Revenue growth per year | — |
| Operating margin | -Infinity% (prior year -Infinity%) |
| Net margin | -Infinity% |
| Operating cash flow | −$190M |
| Capital spending | $440,000 |
| Free cash flow | −$190M |
| Cash | $78M |
| Long-term debt | — |
| Total assets | $330M |
| Total equity | $277M |
| Equity ÷ assets | 83.9% |
| Return on equity | -80.5% |
| Dividend per share | — |
| Dividend years rising | — |

## Readings, computed from those figures

- Altman Z: -10.24 (distress zone)
- Piotroski F: 2 of 9 (weak)
- Health Harbor boat: Weathered boat · two warning signs · operating cash flow was negative (-$190.0M in FY2025); operating loss: a margin of -Infinity% in FY2025

## Edgarette's reading

Exposure: revenue $0K (FY2025). Experience: one year on record; operating margin null, up from null. Soundness: equity 83.9% of assets, return on equity -80.5%. Credibility: four or more audited years, reasonable weight. Against peers (114 filers, $50M+ revenue, pharmaceutical preparations): operating margin null against a -3.8% median.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 2, latest 2026-08-27 ([filing](https://www.sec.gov/Archives/edgar/data/1281895/000114036126034689/0001140361-26-034689-index.htm))

## Recent filings

- 8-K · filed 2026-10-06 · 1.01 Entry into a Material Definitive Agreement; 2.03 Creation of a Direct Financial Obligation; 3.02 Unregistered Sales of Equity Securities; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1281895/000114036126038818/0001140361-26-038818-index.htm)
- 8-K · filed 2026-09-15 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1281895/000114036126036563/0001140361-26-036563-index.htm)
- 8-K · filed 2026-08-27 · 5.02 Departure or Election of Directors; Appointment of Officers · [filing](https://www.sec.gov/Archives/edgar/data/1281895/000114036126034689/0001140361-26-034689-index.htm)
- 8-K · filed 2026-08-10 · 2.02 Results of Operations and Financial Condition; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1281895/000114036126032028/0001140361-26-032028-index.htm)
- 10-Q · filed 2026-08-10 · [filing](https://www.sec.gov/Archives/edgar/data/1281895/000119312526342348/0001193125-26-342348-index.htm)
- 8-K · filed 2026-08-03 · 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/1281895/000114036126030568/0001140361-26-030568-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0001281895.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=1281895

## Cite

POPS4, Edgar & Edgarette: Rocket Pharmaceuticals, Inc. (RCKT) company card, from the company's own SEC filings, accessed 2026-11-04, https://www.pops4.com/boards/company/RCKT. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.